First Patients Enroll in Phase 2 Trial of Acelarin as Treatment for Chemo-resistant Ovarian Cancer

First Patients Enroll in Phase 2 Trial of Acelarin as Treatment for Chemo-resistant Ovarian Cancer
NuCana has started a Phase 2 clinical trial of its ovarian cancer therapy Acelarin (NUC-1031) by enrolling the first patients in the United States and Britain. It will continue to recruit 64 participants who failed to respond to platinum-based chemotherapy. The trial “is a major step in the expansion of the NuCana product pipeline and advances our strategy of

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *